资讯
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therape
Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong